MYALEPT

MYALEPT (metreleptin) is a leptin analog administered by injection that functions as a replacement therapy for leptin deficiency in patients with generalized lipodystrophy, both congenital and acquired forms. The drug works by binding to and activating human leptin receptors, signaling through the JAK/STAT pathway to restore energy homeostasis signaling to the central nervous system. In lipodystrophy patients, leptin deficiency results from loss of adipose tissue, leading to hypertriglyceridemia, ectopic fat deposition in liver and muscle, insulin resistance, and excessive caloric intake. MYALEPT addresses this rare metabolic disorder by restoring leptin-mediated feedback mechanisms that regulate appetite and energy expenditure.